<?xml version="1.0" encoding="UTF-8"?>
<ref id="R4">
 <label>4.</label>
 <mixed-citation publication-type="book">
  <person-group person-group-type="author">
   <name>
    <surname>Moh</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Benalycherif</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Gabillard</surname>
    <given-names>D</given-names>
   </name>
   <etal/>
  </person-group>
  <comment>48-Weeks efficacy of a third-line based on darunavir plus raltegravir regimen in HIV-infected adults who failed second-line protease inhibitor-based regimen in sub-Saharan. Africa, ANRS 12269 THILAO study. 9
   <sup>th</sup> IAS Conference on HIV science; 2017 Jul 23â€“26; Paris, France
  </comment>.
 </mixed-citation>
</ref>
